A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects with Extensive Stage Small Cell Lung Cancer
ENROLLING
Trial ID:
NCT05680922 Protocol # :
23-158
Phase
I
Disease Sites
Lung
Principal Investigator
Sands, Jacob
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #23-158
23-158